Levothyroxine formulations comparison
Pro Research Analysisby 
Searched over 200M research papers
Levothyroxine Formulations: Bioequivalence and Effectiveness
Bioequivalence of Levothyroxine Formulations
Several studies have compared the bioavailability and pharmacokinetics of different levothyroxine (LT4) formulations, including tablets, liquid solutions, and soft gel capsules. Research shows that liquid and soft gel formulations are generally bioequivalent to traditional tablets in healthy volunteers under fasting conditions, with similar absorption rates and maximum plasma concentrations 679. This means that, for most patients, these formulations can be used interchangeably without significant differences in how the drug is absorbed and utilized by the body 679.
Clinical Effectiveness in Special Populations
Infants with Congenital Hypothyroidism
In infants with congenital hypothyroidism, studies comparing liquid and tablet LT4 formulations found that both are effective and safe for normalizing thyroid hormone levels and supporting normal development. However, liquid LT4 may lead to faster normalization of TSH and lower TSH values during treatment, possibly due to higher absorption compared to tablets 25. Despite these differences, both formulations resulted in similar developmental outcomes after one year 25.
Patients with Malabsorption or Interfering Conditions
Liquid and soft gel LT4 formulations may offer advantages for patients with gastrointestinal disorders, those taking multiple medications, or those with conditions that interfere with absorption. These newer formulations are less affected by food, drinks, and certain medications, making them particularly useful for patients who have difficulty achieving stable thyroid hormone levels with tablets 4810. In clinical practice, these alternatives have shown promising results in improving treatment for patients with absorption issues or special needs, such as pediatric patients or those who have undergone bariatric surgery 810.
Comparison of Ethanol-Containing and Ethanol-Free Liquid Formulations
A recent study compared ethanol-containing (e-LT4) and ethanol-free (ef-LT4) liquid LT4 formulations in patients with hypothyroidism. The findings suggest that ef-LT4 may be less effective over time, as indicated by higher TSH and lower fT4 levels after switching from e-LT4, even when the dosage remained the same. This points to potential differences in effectiveness between liquid formulations, highlighting the need for further research .
Safety Profiles of Old and New Formulations
Comparisons between old and new LT4 formulations, including those with updated excipients, show that the safety profiles remain consistent. The types and rates of adverse events are similar, and the overall benefit-risk balance is unchanged, supporting the continued use of new formulations in clinical practice .
Practical Considerations and Areas for Further Research
While new LT4 formulations (liquid and soft gel) may help overcome some limitations of tablets, especially in patients with absorption challenges, the evidence supporting their routine use over tablets in the general population is still limited. More studies are needed to clarify their cost-effectiveness, long-term benefits, and pharmacokinetic mechanisms in various patient groups 48.
Conclusion
Levothyroxine is available in multiple formulations—tablets, liquid solutions, and soft gel capsules—that are generally bioequivalent and safe. Liquid and soft gel forms may offer advantages for patients with absorption issues or special needs, but routine use over tablets is not yet strongly supported by evidence. Differences between specific liquid formulations, such as ethanol-containing versus ethanol-free, may affect effectiveness and require further study. Overall, the choice of formulation should be tailored to individual patient needs and clinical circumstances 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic
Comparison between liquid and tablet formulations of levothyroxine in the initial treatment of congenital hypothyroidism.
There is not complete bioequivalence between drops and tablets in treating infants with congenital hypothyroidism, especially in those with severe form.
Comparison of Safety Profiles of the New and Old Formulations of Levothyroxine in a First Global Introduction in France.
The new levothyroxine formulation's safety profile aligns with the old formulation's, with benefits outweighing risks in approved indications.
DOI